Are their still clinical situations in which you deliberately treat patients with a DOAC besides apixaban?

Thank you for your question. Apixaban has been my preferred agent for a long time for patients requiring therapeutic anticoagulation.

Apixaban’s lower bleeding risk was shown prior to and now has additional evidence to support this with the COBRRA trial. The risk is also ameliorated by the safety in ...